354 related articles for article (PubMed ID: 35582588)
1. Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.
Alonso-Peña M; Sanchez-Martin A; Sanchon-Sanchez P; Soto-Muñiz M; Espinosa-Escudero R; Marin JJG
Cancer Drug Resist; 2019; 2(3):680-709. PubMed ID: 35582588
[TBL] [Abstract][Full Text] [Related]
2. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
[TBL] [Abstract][Full Text] [Related]
3. Role of transportome in the pharmacogenomics of hepatocellular carcinoma and hepatobiliary cancer.
Alonso-Peña M; Espinosa-Escudero RA; Soto-Muñiz M; Sanchon-Sanchez P; Sanchez-Martin A; Marin JJ
Pharmacogenomics; 2019 Aug; 20(13):957-970. PubMed ID: 31486734
[TBL] [Abstract][Full Text] [Related]
4. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
5. Plasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma.
Marin JJG; Macias RIR; Cives-Losada C; Peleteiro-Vigil A; Herraez E; Lozano E
Cells; 2020 Feb; 9(2):. PubMed ID: 32098199
[TBL] [Abstract][Full Text] [Related]
6. Molecular bases of liver cancer refractoriness to pharmacological treatment.
Marin JJ; Romero MR; Briz O
Curr Med Chem; 2010; 17(8):709-40. PubMed ID: 20088759
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs.
Marin JJ; Briz O; Monte MJ; Blazquez AG; Macias RI
Curr Cancer Drug Targets; 2012 May; 12(4):402-38. PubMed ID: 22229248
[TBL] [Abstract][Full Text] [Related]
8. Chemoresistance and chemosensitization in cholangiocarcinoma.
Marin JJG; Lozano E; Herraez E; Asensio M; Di Giacomo S; Romero MR; Briz O; Serrano MA; Efferth T; Macias RIR
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1444-1453. PubMed ID: 28600147
[TBL] [Abstract][Full Text] [Related]
9. Impact of Alternative Splicing Variants on Liver Cancer Biology.
Marin JJG; Reviejo M; Soto M; Lozano E; Asensio M; Ortiz-Rivero S; Berasain C; Avila MA; Herraez E
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008179
[TBL] [Abstract][Full Text] [Related]
10. Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis.
Xue TC; Zhang BH; Ye SL; Ren ZG
Tumour Biol; 2015 Aug; 36(8):5891-9. PubMed ID: 25712376
[TBL] [Abstract][Full Text] [Related]
11. Strategies to enhance the response of liver cancer to pharmacological treatments.
Marin JJG; Macias RIR; Asensio M; Romero MR; Temprano AG; Pereira OR; Jimenez S; Mauriz JL; Di Giacomo S; Avila MA; Efferth T; Briz O
Am J Physiol Cell Physiol; 2024 May; ():. PubMed ID: 38708523
[TBL] [Abstract][Full Text] [Related]
12. Molecular Bases of Chemoresistance in Cholangiocarcinoma.
Marin JJG; Lozano E; Briz O; Al-Abdulla R; Serrano MA; Macias RIR
Curr Drug Targets; 2017; 18(8):889-900. PubMed ID: 25706108
[TBL] [Abstract][Full Text] [Related]
13. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
14. Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma.
Marin JJG; Perez-Silva L; Macias RIR; Asensio M; Peleteiro-Vigil A; Sanchez-Martin A; Cives-Losada C; Sanchon-Sanchez P; Sanchez De Blas B; Herraez E; Briz O; Lozano E
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751679
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Value of Cytokeratin and Sal-Like Protein 4 Expression in Hepatocellular Carcinoma and Intra-Hepatic Cholangiocarcinoma in Taiwan.
Lai YS; Cheng CC; Lee MT; Chao WT; Lai YC; Hsu YH; Liu YH
Int J Med Sci; 2018; 15(14):1746-1756. PubMed ID: 30588199
[No Abstract] [Full Text] [Related]
16. Intrahepatic Cholangiocarcinoma Cells Promote Epithelial-mesenchymal Transition of Hepatocellular Carcinoma Cells by Secreting LAMC2.
Cen W; Li J; Tong C; Zhang W; Zhao Y; Lu B; Yu J
J Cancer; 2021; 12(12):3448-3457. PubMed ID: 33995623
[TBL] [Abstract][Full Text] [Related]
17. Molecular bases of the poor response of liver cancer to chemotherapy.
Marin JJG; Briz O; Herraez E; Lozano E; Asensio M; Di Giacomo S; Romero MR; Osorio-Padilla LM; Santos-Llamas AI; Serrano MA; Armengol C; Efferth T; Macias RIR
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):182-192. PubMed ID: 29544679
[TBL] [Abstract][Full Text] [Related]
18. Models for Understanding Resistance to Chemotherapy in Liver Cancer.
Marin JJG; Herraez E; Lozano E; Macias RIR; Briz O
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31671735
[TBL] [Abstract][Full Text] [Related]
19. Cancer pharmacogenomics: implications on ethnic diversity and drug response.
Patel JN
Pharmacogenet Genomics; 2015 May; 25(5):223-30. PubMed ID: 25751395
[TBL] [Abstract][Full Text] [Related]
20. Germline variants in cancer therapy.
Kaehler M; Cascorbi I
Cancer Drug Resist; 2019; 2(1):18-30. PubMed ID: 35582146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
